Free Trial

Actinium Pharmaceuticals (ATNM) Competitors

Actinium Pharmaceuticals logo
$1.62 -0.01 (-0.31%)
As of 12:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ATNM vs. TRDA, TLSA, TNYA, SLS, MDWD, IPHA, EPRX, CCCC, DERM, and AARD

Should you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Entrada Therapeutics (TRDA), Tiziana Life Sciences (TLSA), Tenaya Therapeutics (TNYA), SELLAS Life Sciences Group (SLS), MediWound (MDWD), Innate Pharma (IPHA), Eupraxia Pharmaceuticals (EPRX), C4 Therapeutics (CCCC), Journey Medical (DERM), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry.

Actinium Pharmaceuticals vs. Its Competitors

Entrada Therapeutics (NASDAQ:TRDA) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 7.6% of Entrada Therapeutics shares are held by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Actinium Pharmaceuticals has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -92.30%. Entrada Therapeutics' return on equity of -17.81% beat Actinium Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Entrada Therapeutics-92.30% -17.81% -14.55%
Actinium Pharmaceuticals N/A -100.85%-47.89%

Entrada Therapeutics currently has a consensus price target of $25.67, indicating a potential upside of 386.11%. Actinium Pharmaceuticals has a consensus price target of $4.50, indicating a potential upside of 178.64%. Given Entrada Therapeutics' higher probable upside, research analysts clearly believe Entrada Therapeutics is more favorable than Actinium Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entrada Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
Actinium Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Entrada Therapeutics had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Entrada Therapeutics and 0 mentions for Actinium Pharmaceuticals. Entrada Therapeutics' average media sentiment score of 0.78 beat Actinium Pharmaceuticals' score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Entrada Therapeutics Positive
Actinium Pharmaceuticals Neutral

Entrada Therapeutics has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500.

Entrada Therapeutics has higher revenue and earnings than Actinium Pharmaceuticals. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entrada Therapeutics$79.48M2.53$65.63M-$1.78-2.97
Actinium PharmaceuticalsN/AN/A-$48.82M-$1.31-1.23

Summary

Entrada Therapeutics beats Actinium Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Get Actinium Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATNM vs. The Competition

MetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$50.38M$869.95M$5.71B$21.60B
Dividend YieldN/A4.84%5.53%3.52%
P/E Ratio-1.161.2076.4129.57
Price / SalesN/A121.10469.6059.26
Price / CashN/A17.6437.4624.72
Price / Book1.236.4813.134.57
Net Income-$48.82M-$5.56M$3.29B$1.00B
7 Day Performance0.31%1.68%2.40%0.55%
1 Month Performance-7.18%5.82%4.42%2.65%
1 Year Performance-10.77%26.09%73.40%14.09%

Actinium Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATNM
Actinium Pharmaceuticals
2.1821 of 5 stars
$1.62
-0.3%
$4.50
+178.6%
-12.0%$50.38MN/A-1.1630
TRDA
Entrada Therapeutics
2.3407 of 5 stars
$5.06
-4.2%
$25.67
+407.2%
-65.1%$200.84M$210.78M-2.84110
TLSA
Tiziana Life Sciences
0.7776 of 5 stars
$1.70
+0.6%
N/A+72.5%$197.47MN/A0.008News Coverage
Gap Up
High Trading Volume
TNYA
Tenaya Therapeutics
2.6634 of 5 stars
$1.20
flat
$6.25
+420.8%
-32.7%$195.57MN/A-1.25110
SLS
SELLAS Life Sciences Group
1.2001 of 5 stars
$1.68
-9.2%
$7.00
+316.7%
+42.9%$194.80M$1M-5.2510
MDWD
MediWound
1.4237 of 5 stars
$17.14
-3.9%
$32.25
+88.2%
+1.9%$192.81M$20.22M-6.4980News Coverage
IPHA
Innate Pharma
2.7591 of 5 stars
$2.07
+3.3%
$11.00
+432.7%
-17.5%$191.38M$12.62M0.00220Analyst Revision
Gap Up
EPRX
Eupraxia Pharmaceuticals
2.1128 of 5 stars
$5.30
-0.4%
$11.00
+107.5%
+101.4%$191.13MN/A-6.2429News Coverage
CCCC
C4 Therapeutics
3.4839 of 5 stars
$3.57
+34.2%
$8.67
+142.8%
-58.0%$189.31M$35.58M-2.26150Analyst Forecast
Gap Up
High Trading Volume
DERM
Journey Medical
2.1289 of 5 stars
$7.12
+0.1%
$12.17
+70.9%
+45.5%$187.06M$56.40M-18.7490Positive News
AARD
Aardvark Therapeutics
3.3126 of 5 stars
$9.95
+15.8%
$32.60
+227.6%
N/A$186.38MN/A0.0018News Coverage
Analyst Forecast
High Trading Volume

Related Companies and Tools


This page (NYSE:ATNM) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners